
    
      Children and adolescents with chronic hepatitis B and compensated liver, HBeAg-positive and
      serum HBV DNA positive (greater than or equal to 1 x 100,000 copies/mL by Roche Amplicor
      Monitor PCR) received doses of adefovir dipivoxil in a cross-over design. Subjects aged 2-11
      received two single doses (0.14 mg/kg and 0.3 mg/kg liquid formulation) and subjects 2-17
      received one dose (10 mg liquid formulation).
    
  